Mechanism of Action

COMBINATION THERAPY

LYNPARZA in combination with abi/pred for initial treatment of BRCAm mCRPC

2 distinct mechanisms of action working in parallel in mCRPC1-5*

LYNPARZA MOA in mCRPC Combination TherapyLYNPARZA MOA in mCRPC Combination Therapy

In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP-enzymatic activity and increased formation of trapped PARP-DNA complexes, resulting in DNA damage and cancer cell death. LYNPARZA may also affect healthy cells and tissues in the body.

In prostate cancer models, PARP1 has been shown to contribute to androgen receptor (AR) activity regulation; the combination of olaparib and AR inhibition resulted in cytotoxicity in vitro and anti-tumor activity in mouse xenograft models.

*The exact mechanism of action of LYNPARZA remains a subject of research.

MONOTHERAPY

For patients with HRRm mCRPC following progression on prior enzalutamide or abiraterone

LYNPARZA targets PARP to disrupt the DNA-repair process and potentially kill tumor cells1-4*

LYNPARZA MOA in mCRPC MonotherapyLYNPARZA MOA in mCRPC Monotherapy

In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP-enzymatic activity and increased formation of trapped PARP-DNA complexes, resulting in DNA damage and cancer cell death. LYNPARZA may also affect healthy cells and tissues in the body.

*The exact mechanism of action of LYNPARZA remains a subject of research.